ASHVIN PATEL: Open Payments
NPI 1730209172 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,037 in 142 payments from 14 companies in 2025. Trend: 2023 $13,738 · 2024 $7,535 · 2025 $3,037
Food & beverage: $3,037
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $536 |
| Vanda Pharmaceuticals Inc. | 16 | $532 |
| Alkermes, Inc. | 13 | $329 |
| Neurocrine BioSciences, Inc. | 12 | $297 |
| E.R. Squibb & Sons, L.L.C. | 10 | $239 |
| Collegium Pharmaceutical, Inc. | 15 | $200 |
| Janssen Pharmaceuticals, Inc | 7 | $197 |
| ABBVIE INC. | 14 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $150 |
| Lundbeck LLC | 8 | $145 |
Products named: CAPLYTA, FANAPT, ARISTADA, INGREZZA, COBENFY, Jornay PM, VRAYLAR, SPRAVATO.
Industry payments across VA — which companies pay providers there.
